- Home
- SITC vs PLX Comparison
SITC vs PLX Comparison
Compare SITC & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SITC | PLX |
|---|---|---|
| Founded | 1965 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.8M | 207.1M |
| IPO Year | 1994 | 1996 |
Fundamental Metrics
Financial Performance| Metric | SITC | PLX |
|---|---|---|
| Price | $3.74 | $2.56 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.1M | 836.2K |
| Earning Date | 11-02-2026 | 08-12-2026 |
| Dividend Yield | ★ 106.95% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | ★ $123,649,000.00 | $52,744,000.00 |
| Revenue This Year | N/A | $55.77 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.46 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.80 | $1.65 |
| 52 Week High | $8.91 | $3.19 |
Technical Indicators
Market Signals| Indicator | SITC | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 72.09 | 42.44 |
| Support Level | $2.89 | $2.21 |
| Resistance Level | $4.55 | $2.75 |
| Average True Range (ATR) | 0.13 | 0.10 |
| MACD | 0.07 | -0.02 |
| Stochastic Oscillator | 88.56 | 19.67 |
Price Performance
Historical ComparisonAbout SITC SITE Centers Corp.
SITE Centers Corp is a self-administered and self-managed REIT that operates as a fully integrated real estate company. The company is engaged in the business of owning, leasing, acquiring, redeveloping, developing, and managing shopping centers.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.